Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas (CONTACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01563133|
Recruitment Status : Active, not recruiting
First Posted : March 26, 2012
Last Update Posted : August 29, 2017
This study focuses on three different lesions: pancreatic cysts, lymph nodes near the gastrointestinal tract and pancreatic masses.
On one hand, the results obtained during previous studies are more advanced for the assessment of the diagnostic performance of Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system for Pancreatic cysts. Safety and technical feasibility have already been performed, and an interpretation criteria classification exists. On the other hand, results for pancreatic masses and Lymph nodes are less developed.
The study therefore comprises two sub-studies, one on the pancreatic cysts, and another on pancreatic masses and lymph nodes.
Cysts The primary hypothesis of the study is that using nCLE in addition to EUS-FNA and tissue sampling allows better characterization of pancreatic cysts and improves appropriate therapeutic decision-making.
For physicians, integrating nCLE into the diagnostic algorithm of pancreatic cysts could impact patient management by :
- Ruling out malignancy for patients with benign appearing nCLE images.
- Characterizing more malignant tumors in the pancreas.
- Pancreatic masses and Lymph nodes The primary hypothesis of the study is that in vivo imaging of lymph-nodes near the gastrointestinal tract and pancreatic masses during EUS-FNA procedures is feasible and that descriptive criteria can be defined to further differentiate the different types of lesions.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cyst Pancreatic Neoplasms Pancreatic Adenoma Pancreatic Cancer Pancreatic Islet Cell Tumors Lymph Node Lymphadenopathy||Procedure: EUS-FNA Device: nCLE||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||330 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Evaluation Of NCLE in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||March 2, 2016|
|Estimated Study Completion Date :||March 2019|
|Lymph nodes, pancreatic masses & cysts||
Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
needle-based Confocal Laser Endomicroscopy
- Diagnostic performance of the Cellvizio nCLE system in the characterization of pancreatic cysts [ Time Frame: Within 6 months after the end of Follow-up period ]
- Descriptive criteria in nCLE sequences for the characterization of pancreatic masses and lymph nodes [ Time Frame: Within one year after the end of the follow-up period ]
- Impact of the Cellvizio nCLE system on the management of a patient with pancreatic cyst [ Time Frame: Within one year after the end of the follow-up period ]
- Validation of the interpretation criteria classification for pancreatic cysts [ Time Frame: within 6 months after the end of the follow-up period ]
- Atlas of images of nCLE sequences of pancreatic masses and lymph nodes during EUS-FNA [ Time Frame: within 3 months of the end of the follow-up period ]
- Diagnostic performance of nCLE in the diagnosis of pancreatic masses and lymph nodes, when associated with other diagnostic information [ Time Frame: within one year after the end of the follow-up period ]
- Feasibility and safety data on nCLE during EUS-FNA procedure [ Time Frame: Within 3 months after the end of the enrollment period ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01563133
|Lomme, France, 59462|
|Hôpital Jean Mermoz|
|Lyon, France, 69008|
|Institut Paoli Calmettes|
|Marseille, France, 13273|
|Principal Investigator:||Marc Giovannini, MD||Institut Paoli-Calmettes|